Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 or the Childhood Cancer STAR Reauthorization Act This bill reauthorizes through FY2028 and modifies pediatric cancer research and related programs, including to expand collection of and access to relevant biospecimens and to support the transition of pediatric cancer survivors to primary care.
LOBBYING ON THIS BILL
35 federal lobbying reports name this bill in their activity descriptions · LDA disclosures
⟳ The revolving door — lobbyists on this bill with disclosed former government roles
“Covered position” is the former government job lobbyists must disclose by law (LDA §4). Prior service is stated on the filings; it carries no implication of wrongdoing. Full revolving-door board →
A report naming a bill means the organization disclosed lobbying activity on it — the disclosure does not state a position for or against.
VOTE BREAKDOWN
No recorded floor vote
Most bills never receive a recorded roll-call vote — they're referred to committee and don't advance to the floor. The sponsor and funding context on this page still tells you who is behind it and what industries have a stake.
SPONSORS

Jack Reed
D-RI · Primary
29 COSPONSORS
BIPARTISAN





+23 more (see dot grid above)
SPONSOR FUNDING
Top industries funding Reed
TRAIL AI
The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Reauthorization Act, introduced by Senator Jack Reed of Rhode Island, reauthorizes federal programs related to childhood cancer survivorship and research. The bill was signed into law during the 117th Congress. Specific voting data for this legislation is not yet available.
Based on public voting records. Does not imply causation.
TIMELINE
DATA SOURCES
Bill data: Congress.gov · 117th–119th Congress (2021–present)
Vote records: House Clerk / Senate · 2021–present
Reflects public records. Does not imply causation.